Vaidya Sane Ayurved Laboratories Ltd Q2 FY2025 Concall Summary

Key Takeaways

• Revenue down, profit up: Revenue fell 18.20% YoY to Rs. 41.80 crores in H1 FY25, but PAT more than doubled to Rs. 3.26 crores as cost discipline kicked in across the board.
• Cost structure permanently reset: HR costs, COGS, and professional fees all dropped as a percentage of revenue, driven by a shift from product-only online sales to an integrated clinic-plus-services model and renegotiated partner contracts.
• Hospitals are the new profit engine: Management is prioritizing hospital expansion over clinics and FMCG, citing hospital EBITDA margins that can exceed 50% with higher occupancy, and has outlined a capital-light acquisition model to scale.
• Full-year guidance is flat revenue, better profit: Management expects to match last year's Rs. 97–100 crores turnover with improved EBITDA, betting that operating leverage will convert any topline recovery directly into margin gains.
• What to watch next quarter: Progress on CGHS and Ayushman Bharat empanelment, the pace of Khopoli hospital bed additions once government permissions arrive, and whether the diabetes awareness campaign translates into a measurable patient volume uptick.

Revenue Decline & The Profitability Flip

• Topline contracted sharply: Revenue from operations fell to Rs. 41.80 crores in H1 FY25 from Rs. 51.10 crores in H1 FY24, a drop management attributes partly to deliberately walking away from low-margin online product sales through the Vaidya Sane channel.
• EBITDA more than doubled: EBITDA excluding other income rose 115% to Rs. 5.76 crores, and PAT jumped to Rs. 3.26 crores from Rs. 1.18 crores, proving the cost reset is structural rather than a one-off.
• Three cost levers pulled simultaneously: HR costs fell from 27.5% to 24.5–25% of revenue; COGS dropped from 28–29% to 22–23% as the mix shifted from product-only to product-plus-services through clinics and hospitals; professional fees were renegotiated down from 9.5–10% to 7–7.1%.
• Professional fees are now a variable, per-patient cost: The company renegotiated with existing partners and found newer ones offering better rates for modern diagnostic reporting (2D Echo, stress test, ECG, PFT) required in the integrated model, reducing the per-patient cost.
• Marketing strategy pivoted to treatment-first: Earlier campaigns pushed products; now the focus is on treatment modalities through digital media, television, and BTL campaigns, a shift designed to pull patients into the clinic and hospital ecosystem where margins are higher.

Dr. Rohit Madhav Sane: "Increase in the topline is going to add directly to the EBITDA."

Hospital Expansion: The Core Growth Bet

• Hospitals are now the top capital-allocation priority: Management explicitly ranked hospitals first, clinics second, and FMCG a distant third, because hospital EBITDA margins are "quite strong as compared to others."
• Khopoli hospital adding 100 beds in phases: The plan is to add roughly 100 beds over 12–18 months on adjacent land, starting with 20–40 beds at a time, at a total cost of Rs. 8–10 crores funded internally; government permissions are pending and expected in about a month.
• Nagpur hospital adding 20 beds: Expansion in the same 12–18 month window, using existing available space.
• Capital-light acquisition model defined: Instead of greenfield builds, the company will acquire underperforming resorts or existing hospitals with a minimum 50-bed capacity and convert them into Madhavbaug facilities, adopting a franchise-like structure where treatment protocols stay under Madhavbaug control and the franchise partner handles infrastructure.
• Geography focus narrowed: North India, Gujarat, and Rajasthan are the priority markets; Rajasthan is particularly attractive because the state government has already accredited Ayurveda for pensioners and government employees.
• No new hospital for 6–8 months: Near-term focus is on consolidating existing facilities and refining marketing and messaging strategies; management will turn more aggressive on bed count next year.
• Long-term ambition set for 2030: The target is 1,000 clinics, 10 hospitals, and 5,000 outpatient departments, with a particular focus on rural areas, plus training 10,000 Ayurvedic physicians through the Institute of Preventive Cardiology.

Dr. Rohit Madhav Sane: "Instead of investing in new infrastructure we plan to acquire existing hospitals or resorts and convert them into Madhavbaug facilities thus adopting a franchise like model for growth looking for future hospitals in North India, Gujarat and few in the South of India also."

Margin Structure & Operating Leverage

• Current EBITDA margins vary widely by segment: Hospitals operate in a 30–55% EBITDA range depending on occupancy; clinics run at 5–10%; management did not disclose a blended or segment-weighted figure.
• The operating leverage thesis is explicit: HR costs are largely fixed, COGS is expected to stay capped around 22–24%, professional fees will not rise proportionally, and rent and taxes are stable, so incremental revenue should convert to EBITDA at a very high rate.
• Hospital margins can exceed 50%: As occupancy rises across all three hospitals, management believes the hospital segment's EBITDA margin can cross 50%, making it the highest-return part of the business.
• Clinic margins have headroom too: Clinics already operate at roughly 70% gross margin, and with current slot utilization at only 45–50%, there is room to expand timings and patient volume without adding fixed costs.
• Professional fees will keep declining as a percentage: The absolute spend may rise modestly with patient volume, but management expects the percentage-of-revenue figure to improve further from the current 7% level and not return to last year's H1 peak.

Government Empanelment & Institutional Channel

• CGHS application in motion: The company has started approaching CGHS and plans to apply for all government agency empanelments within the next 4–6 months; a dedicated hire for this function is expected in about a month.
• Ayushman Bharat readiness is high: The scheme is yet to launch its 50–70 Ayurvedic treatment packages, but the company already has a NABH-accredited hospital, land acquired, and the ability to shift from one patient per room to two, increasing occupancy capacity by 50–60%.
• Clinic capacity can triple under Ayushman Bharat: Management estimates the existing clinic model can accommodate three times more patients than current volumes, and the hospital setup can handle a similar multiple, positioning the company to absorb a surge if the scheme opens.
• Rajasthan government already on board: The state has accredited Ayurveda for its pensioners and government employees, creating an immediate addressable institutional market without waiting for central schemes.

Dr. Rohit Madhav Sane: "I am quite strong and confident about it that once the Ayushman Bharat is open for actual Ayurveda patients I think we are in a good position to accommodate those patients."

FMCG & Madhavprash: A Slow-Burn Third Leg

• Madhavprash sold 13,000 units online in six months: Sales are routed through the subsidiary Dynamic and available on Tata 1mg, Flipkart, and Amazon; the target is to double that number in the coming six months.
• Retail expansion is on the back burner: Management is concentrating on the online channel for now and will increase physical retail availability only gradually.
• FMCG is the lowest-priority segment: The long-term business mix target is 50–60% hospitals, with the remainder split between clinics and FMCG at roughly 10–20%, reflecting the margin hierarchy that drives capital allocation.

Diabetes Campaign & Brand-Building

• World Diabetes Day event generated clinical proof points: On November 10, 1,300 patients who had become diabetes-free in 90 days participated; 75% tested normal on a Glucose Tolerance Test after consuming 75g of glucose, and 10–15% showed impaired results, with modern physicians from various institutes present to validate the outcomes.
• The campaign is a patient-acquisition funnel: Management expects the event to boost brand credibility among both patients and referring doctors, which should translate into higher patient volumes in the coming months.
• 'Azadi Diabetes Se' campaign ran across 90+ clinics: Launched in August, it included a Mega Glucose Tolerance Test event with over 200 Type 2 Diabetes patients who had achieved normal blood glucose levels without allopathic medications.

Dr. Rohit Madhav Sane: "This will help us to showcase our confidence through our doctors as well as through our patients who had participated in this event and this will help us to boost the total brand value in the patients mind which will again help us to have more numbers of patients in the coming months."

Guidance & Commitments

Key Metrics